Tags

Type your tag names separated by a space and hit enter

The underlying mechanism of metabolic syndrome on benign prostatic hyperplasia and prostate volume.
Prostate. 2020 05; 80(6):481-490.P

Abstract

OBJECTIVE

To investigate the potential mechanism of the effect of metabolic syndrome (MetS) on prostate volume (PV) and the risk of benign prostatic hyperplasia (BPH)/lower urinary tract symptoms (LUTS) and the relationships of MetS and the major pathogenic factors of MetS with the clinical progression of BPH/LUTS in older Chinese men.

SUBJECTS AND METHODS

We analyzed clinical data obtained from 506 ostensibly healthy men who underwent routine health check-ups and recruited 415 subjects from a group of previously studied men after 4 years. We evaluated the associations of major pathological factors of MetS, including insulin resistance, subclinical inflammatory state, and sex hormone changes, with PV, the risk of BPH and the clinical progression of BPH/LUTS by using multiple linear regression and logistic regression.

RESULTS

After adjustment for age, insulin, HOMA (homeostatic model assessment) index, leptin, resistin, adiponectin, C-reactive protein, tumor necrosis factor-α (TNF-α), sex hormone-binding globulin, and testosterone levels were significantly associated with PV (all P < .05), and in the age-adjusted logistic regression model, positive associations of resistin and TNF-α with BPH/LUTS were found (OR, 1.662, P = .007 and OR, 1.044, P < .001, respectively). Predictors of BPH/LUTS clinical progression were significantly correlated with MetS and TNF-α. The group with higher TNF-α levels had a higher rate of newly diagnosed BPH (9.5% vs 19.1%, P = .006) and a greater increase in PV levels (0.61 ± 0.08 vs 1.09 ± 0.35 cm3 , P <.001) after 4 years.

CONCLUSIONS

MetS and its pathological factors were associated with an increased PV and an increased risk of BPH/LUTS that is more prone to clinical progression. TNF-α may serve as an early biological indicator to identify which patients with BPH/LUTS are at higher risk of unfavorable outcomes.

Authors+Show Affiliations

Department of Urology, Capital Medical University, Beijing, China.Department of Urology, Capital Medical University, Beijing, China.Department of Urology, Capital Medical University, Beijing, China.Department of Urology, Capital Medical University, Beijing, China.Department of Urology, Capital Medical University, Beijing, China.Department of Urology, Capital Medical University, Beijing, China.Department of Urology, Capital Medical University, Beijing, China.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32104919

Citation

Xia, Bo-Wen, et al. "The Underlying Mechanism of Metabolic Syndrome On Benign Prostatic Hyperplasia and Prostate Volume." The Prostate, vol. 80, no. 6, 2020, pp. 481-490.
Xia BW, Zhao SC, Chen ZP, et al. The underlying mechanism of metabolic syndrome on benign prostatic hyperplasia and prostate volume. Prostate. 2020;80(6):481-490.
Xia, B. W., Zhao, S. C., Chen, Z. P., Chen, C., Liu, T. S., Yang, F., & Yan, Y. (2020). The underlying mechanism of metabolic syndrome on benign prostatic hyperplasia and prostate volume. The Prostate, 80(6), 481-490. https://doi.org/10.1002/pros.23962
Xia BW, et al. The Underlying Mechanism of Metabolic Syndrome On Benign Prostatic Hyperplasia and Prostate Volume. Prostate. 2020;80(6):481-490. PubMed PMID: 32104919.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The underlying mechanism of metabolic syndrome on benign prostatic hyperplasia and prostate volume. AU - Xia,Bo-Wen, AU - Zhao,Si-Cong, AU - Chen,Zong-Ping, AU - Chen,Chao, AU - Liu,Tian-Shu, AU - Yang,Fan, AU - Yan,Yong, Y1 - 2020/02/27/ PY - 2019/09/14/received PY - 2020/02/04/accepted PY - 2020/2/28/pubmed PY - 2020/7/16/medline PY - 2020/2/28/entrez KW - benign prostatic hyperplasia KW - lower urinary tract symptoms KW - metabolic syndrome KW - prostate volume KW - tumor necrosis factor-α SP - 481 EP - 490 JF - The Prostate JO - Prostate VL - 80 IS - 6 N2 - OBJECTIVE: To investigate the potential mechanism of the effect of metabolic syndrome (MetS) on prostate volume (PV) and the risk of benign prostatic hyperplasia (BPH)/lower urinary tract symptoms (LUTS) and the relationships of MetS and the major pathogenic factors of MetS with the clinical progression of BPH/LUTS in older Chinese men. SUBJECTS AND METHODS: We analyzed clinical data obtained from 506 ostensibly healthy men who underwent routine health check-ups and recruited 415 subjects from a group of previously studied men after 4 years. We evaluated the associations of major pathological factors of MetS, including insulin resistance, subclinical inflammatory state, and sex hormone changes, with PV, the risk of BPH and the clinical progression of BPH/LUTS by using multiple linear regression and logistic regression. RESULTS: After adjustment for age, insulin, HOMA (homeostatic model assessment) index, leptin, resistin, adiponectin, C-reactive protein, tumor necrosis factor-α (TNF-α), sex hormone-binding globulin, and testosterone levels were significantly associated with PV (all P < .05), and in the age-adjusted logistic regression model, positive associations of resistin and TNF-α with BPH/LUTS were found (OR, 1.662, P = .007 and OR, 1.044, P < .001, respectively). Predictors of BPH/LUTS clinical progression were significantly correlated with MetS and TNF-α. The group with higher TNF-α levels had a higher rate of newly diagnosed BPH (9.5% vs 19.1%, P = .006) and a greater increase in PV levels (0.61 ± 0.08 vs 1.09 ± 0.35 cm3 , P <.001) after 4 years. CONCLUSIONS: MetS and its pathological factors were associated with an increased PV and an increased risk of BPH/LUTS that is more prone to clinical progression. TNF-α may serve as an early biological indicator to identify which patients with BPH/LUTS are at higher risk of unfavorable outcomes. SN - 1097-0045 UR - https://www.unboundmedicine.com/medline/citation/32104919/The_underlying_mechanism_of_metabolic_syndrome_on_benign_prostatic_hyperplasia_and_prostate_volume_ L2 - https://doi.org/10.1002/pros.23962 DB - PRIME DP - Unbound Medicine ER -